drugset / Trial / NCT06223958
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration
Phase 3
Active not recruiting
344 enrolled
Ocular Therapeutix, Inc.
Duke University · collabFortrea · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (axitinib implant) in Subjects with Neovascular Age-Related Macular Degeneration
Timeline
- Start
- 2024-01-29
- Primary completion
- 2026-04-29
- Completion
- 2027-09-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aflibercept | Protein / enzyme biologic | 2 mg | — |
| Subject | Axitinib | Small molecule | — | Intravitreal |